Selinexor Trials Resume

Selinexor Trials Back on Track as FDA Lifts Partial Clinical Hold

In his blog this week, IMF Chairman Dr. Brian Durie reports on news today that the US Food & Drug Administration has lifted a partial hold issued earlier this month on clinical trials with selinexor. “It is always difficult to introduce a first-in-class agent—especially now, since many options are available for myeloma patients,” he notes. “However, the ‘unmet need’ remains, since patients still run out of options.” To read his blog, click HERE.

Join Today's Webinar on the Recent Lack of Funds for Co-Pay Assistance

Recently, the International Myeloma Foundation’s InfoLine has been flooded with calls from patients and caregivers facing insurmountable financial challenges due to the high cost of drugs and increases in insurance copays. In the past, several services have been available to provide financial assistance to patients. We understand that funds for co-pay assistance are difficult to come by, and available funding will likely dry up quickly. Click HERE to register for today’s webinar at 4 PM PT / 7 PM ET on this topic. This forum is for you to share your stories, and for all of us, to explore possible solutions to these hurdles to co-pay assistance.

 

Myeloma Patients Around the World Declare March 30th as International Myeloma Action Day

The Global Myeloma Action Network (GMAN), a group of patient organizations in five continents, has declared today, March 30th, as International Myeloma Action Day. The IMF asks myeloma patients and advocates to join GMAN's first "MAM goes MAD" campaign today by sharing their stories on social media platforms (including Twitter with hashtag #GMANmad17). Patients also will send letters to both their doctors advocating for early detection, and to policy makers in their local areas to support access to new drug therapies. Learn more HERE.

 

The Journal Leukemia Publishes Article on Next-Generation Flow

The article “Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma” was published in the latest issue of the journal Leukemia. This article, co-authored by many International Myeloma Working Group investigators and other clinicians, reports on how a novel next-generation flow approach has been developed for highly sensitive and standardized minimal residual disease (MRD) detection of multiple myeloma. Access the article HERE.

 

 

Overall Survival Data from Kyprolis (carfilzomib) Phase III Trial Presented at 16th International Myeloma Workshop

The interim analysis of the phase III head-to-head ENDEAVOR trial demonstrated positive results for overall survival (OS), as presented at the16th International Myeloma Workshop in New Delhi. For information about this trial, please visit clinicaltrials.gov under trial identification number NCT01568866 or this news release from Amgen.

 

IMF Activity in Europe for 2017 Is Off to a Strong Start

On Saturday, March 25th, the IMF and the MijelomCRO hosted the very first Croatian Patient & Family Seminar in the beautiful city of Opatija. MijelomCRO was founded by Mira Armour, Director of the organization; her brother Goran Tudor, the President; and her sister Ana Tudor; Honorary Secretary. After their mother passed from multiple myeloma in 2011, they decided, as former caregivers, to create MijelomCRO to support others in their myeloma journeys. Since then they have been doing tremendous work all over the country, including for emerging programs in neighboring Bosnia. A recipient of the Susie Novis Durie Grant and a GMAN member, MijelomCRO will hold its second Patient & Family Seminar in Zagreb later this year. Nadia Elkebir, Director of IMF Europe said, “MijelomCRO’s Director Mira Armour and her family go way beyond the needs of myeloma patients in their country. It is overwhelming to be part of this success largely deserved, and I look forward to our next collaboration.” For more information on MijelomCRO, click HERE.

 

 


We Would Like to Thank Our Sponsors: Takeda, Celgene, Amgen, and Bristol-Myers Squibb